BOSTON, September 16, 2021: Morgan Lewis is representing Avitide Inc. in its acquisition by Repligen Corp., a global life sciences company focused on bioprocessing technology leadership. Avitide discovers, develops, manufactures, and supplies custom and catalog affinity purification solutions to the biopharmaceutical industry.
The transaction is valued at approximately $150 million, composed of $75 million in cash plus $75 million in Repligen common stock, in addition to performance-based earnout payments over the next three years. The transaction, announced September 16, is expected to be completed during the third quarter of 2021, subject to the satisfaction of customary closing conditions.
The Morgan Lewis team advising Avitide is partners Mark Stein and Mark Opitz and associate Greer Longer.
For more, read the company’s announcement.